The present study considers three questions: first, whether the eGF triple therapy treatment (VEGF-A-PlGF-2123–144, PDGF-BB-PlGF-2123–144, and HB-EGF-PlGF-2123–144) has a statistically significant effect on wound healing for mice with T1D; second, whether addition of HB-EGF-PlGF-2123–144 to the dual combination was beneficial; and third, the specific way in which the cellular milieu of a wound affects healing upon treatment. This evidence concerns the gene VEGFA and type 1 diabetes mellitus.